Therefore, when considering the shorter survival of STS patients expressing IL4Rα and IL13Rα1, therapeutics targeting IL4Rα and IL13Rα1 might be novel therapeutic strategems for the treatment of STSs. The gene discussed is IL4R; the disease is telomere syndrome.